StockData
ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Anika Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$20.22+0.24 (+1.20%)

Close on Oct 19, 2026

Market cap
$277.36M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 4, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 29, 2026Before market open$32.60M$0.24–
Q1 FY2026
Ended Mar 31, 2026
Apr 29, 2026Before market open$29.60M$-0.37$0.27
Q4 FY2025
Ended Dec 31, 2025
Feb 26, 2026Before market open$30.60M$0.13$0.31
Q3 FY2025
Ended Sep 30, 2025
Nov 5, 2025Before market open$27.80M–$0.04
Q2 FY2025
Ended Jun 30, 2025
Jul 30, 2025Before market open$28.20M$-0.33$-0.13
Q1 FY2025
Ended Mar 31, 2025
May 9, 2025Before market open$26.20M$-0.28$-0.06
Q4 FY2024
Ended Dec 31, 2024
Mar 12, 2025During market hours$30.60M$-0.17$-0.03
Q3 FY2024
Ended Sep 30, 2024
Oct 31, 2024Before market open$38.80M$-2.03$-0.25
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024During market hours–––
Q1 FY2024
Ended Mar 31, 2024
May 8, 2024During market hours–––
Q4 FY2023
Ended Dec 31, 2023
Mar 13, 2024During market hours–––

Company guidance

Outlook given with results on Jul 29, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Adjusted EBITDA marginnon-GAAPfull-year 202613% to 17%Raised
Total Company Revenue Guidancefull-year 20265% to 10% growthLowered
OEM Channel revenue growth20260% to 5% growthLowered
Commercial Channel revenue growth202612% to 18% growthRaised
Commercial Channel revenue growth20275% to 15% growthNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Anika Therapeutics filed with the SEC